176 related articles for article (PubMed ID: 31827111)
1. CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models.
Huizing FJ; Garousi J; Lok J; Franssen G; Hoeben BAW; Frejd FY; Boerman OC; Bussink J; Tolmachev V; Heskamp S
Sci Rep; 2019 Dec; 9(1):18898. PubMed ID: 31827111
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.
Huizing FJ; Hoeben BAW; Franssen GM; Boerman OC; Heskamp S; Bussink J
Mol Pharm; 2019 Feb; 16(2):701-708. PubMed ID: 30550290
[TBL] [Abstract][Full Text] [Related]
3. Preclinical validation of
Huizing FJ; Hoeben BAW; Franssen G; Lok J; Heskamp S; Oosterwijk E; Boerman OC; Bussink J
Radiother Oncol; 2017 Sep; 124(3):521-525. PubMed ID: 28789809
[TBL] [Abstract][Full Text] [Related]
4. Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models.
Huizing FJ; Hoeben BAW; Lok J; Boerman OC; Heskamp S; Bussink J
Phys Imaging Radiat Oncol; 2021 Jul; 19():145-150. PubMed ID: 34485720
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
Garousi J; Huizing FJ; Vorobyeva A; Mitran B; Andersson KG; Leitao CD; Frejd FY; Löfblom J; Bussink J; Orlova A; Heskamp S; Tolmachev V
Sci Rep; 2019 Oct; 9(1):14907. PubMed ID: 31624303
[TBL] [Abstract][Full Text] [Related]
6. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
7. Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells.
van Lith SAM; Huizing FJ; Franssen GM; Hoeben BAW; Lok J; Doulkeridou S; Boerman OC; Gotthardt M; van Bergen En Henegouwen PMP; Bussink J; Heskamp S
Mol Pharm; 2022 Oct; 19(10):3511-3520. PubMed ID: 35044182
[TBL] [Abstract][Full Text] [Related]
8. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
[TBL] [Abstract][Full Text] [Related]
9. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines.
Troost EG; Bussink J; Kaanders JH; van Eerd J; Peters JP; Rijken PF; Boerman OC; van der Kogel AJ
Radiother Oncol; 2005 Aug; 76(2):194-9. PubMed ID: 16024110
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
Tafreshi NK; Lloyd MC; Proemsey JB; Bui MM; Kim J; Gillies RJ; Morse DL
Mol Imaging Biol; 2016 Apr; 18(2):219-31. PubMed ID: 26276155
[TBL] [Abstract][Full Text] [Related]
12. Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.
Garousi J; Honarvar H; Andersson KG; Mitran B; Orlova A; Buijs J; Löfblom J; Frejd FY; Tolmachev V
Mol Pharm; 2016 Nov; 13(11):3676-3687. PubMed ID: 27529191
[TBL] [Abstract][Full Text] [Related]
13. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
[TBL] [Abstract][Full Text] [Related]
14. Targeting CAIX with [
Yang X; Zhu H; Yang X; Li N; Huang H; Liu T; Guo X; Xu X; Xia L; Deng C; Tian X; Yang Z
Mol Pharm; 2019 Apr; 16(4):1532-1540. PubMed ID: 30803240
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.
Carlin S; Khan N; Ku T; Longo VA; Larson SM; Smith-Jones PM
PLoS One; 2010 May; 5(5):e10857. PubMed ID: 20523727
[TBL] [Abstract][Full Text] [Related]
16. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
17. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models.
Boreel DF; Span PN; Kip A; Boswinkel M; Peters JPW; Adema GJ; Bussink J; Heskamp S
Mol Pharm; 2023 Apr; 20(4):2245-2255. PubMed ID: 36882391
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.
Lou Y; McDonald PC; Oloumi A; Chia S; Ostlund C; Ahmadi A; Kyle A; Auf dem Keller U; Leung S; Huntsman D; Clarke B; Sutherland BW; Waterhouse D; Bally M; Roskelley C; Overall CM; Minchinton A; Pacchiano F; Carta F; Scozzafava A; Touisni N; Winum JY; Supuran CT; Dedhar S
Cancer Res; 2011 May; 71(9):3364-76. PubMed ID: 21415165
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
